Heart failure: Molecular, genetic and epigenetic features of the disease

Minerva Cardioangiologica

Volumn 60, Issue 6, 2012, Pages 593-609

  D'Alessandro, R ^a   Roselli, T ^a   Valente, F ^a   Iannaccone, M ^a   Capogrosso, C ^a   Petti, G ^a   Alfano, G ^a   Masarone, D ^a   Ziello, B ^a   Fimiani, F ^a   Pacileo, G ^a   Russo, M G ^a   Calabro P ^a   Limongelli, G ^a   Maddaloni, V ^a   Calabro R ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Epigenomics; Genetics; Heart failure

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATASE (POTASSIUM); ADENOSINE TRIPHOSPHATE; ALPHA TROPOMYOSIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL L TYPE; CALCIUM ION; CAVEOLIN 3; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DYSTROPHIN; ENDOTHELIN 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; ISOLEUCINE TRANSFER RNA; LEUCINE TRANSFER RNA; LYSINE TRANSFER RNA; METAVINCULIN; MYOSIN; MYOSIN HEAVY CHAIN BETA; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SERINE TRANSFER RNA; SODIUM CHANNEL; SYNTROPHIN; TRANSFER RNA; TROPOMYOSIN; TROPONIN C; TROPONIN I; TROPONIN T; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCULIN;

CELL MEMBRANE; CLINICAL FEATURE; CONGESTIVE CARDIOMYOPATHY; DESMOSOME; EPIGENETICS; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE MUTATION; GENETIC SUSCEPTIBILITY; HEART FAILURE; HEART INFARCTION; HEART MITOCHONDRION; HEART MUSCLE; HEART MUSCLE CELL; HISTOPATHOLOGY; HUMAN; HYPERTENSION; HYPERTROPHIC CARDIOMYOPATHY; LONG QT SYNDROME; MOLECULAR BIOLOGY; MOLECULAR GENETICS; MYOCARDIAL DISEASE; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PROGNOSIS; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REVIEW; RISK FACTOR; SARCOMERE; SINGLE NUCLEOTIDE POLYMORPHISM; TELOMERE; THIN FILAMENT;

DESMOSOMES; EPIGENOMICS; GENE EXPRESSION REGULATION; GENE-ENVIRONMENT INTERACTION; HEART FAILURE; HUMANS; MUTATION; MYOCARDIAL CONTRACTION;

EID: 84873497689     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (102)

1. Gheorghiade M, Bonow RO. Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation 1998;97:282-9. (Pubitemid 28067315)
2. Hill JA, Olson EN. Cardiac plasticity. N Engl J Med 2008 27;358:1370-80.
3. Katz AM. The "Modern" view of heart failure how did we get here? Circulation: Heart Failure 2008;1:63-71.
4. Neubauer S. The failing heart - an engine out of fuel. N Engl J Med 2007;356:1140-51. (Pubitemid 46425598)
5. Morita H, Seidman J, Seidman CE. Genetic causes of human heart failure. J Clin Invest 2005;115:518-26. (Pubitemid 40322221)
6. Flashman E, Redwood C, Moolman-Smook J, Watkins H. Cardiac myosin binding protein c its role in physiology and disease. Circ Res 2004;94:1279-89. (Pubitemid 38724473)
7. LeWinter MM, Wu Y, Labeit S, Granzier H. Cardiac titin: Structure, functions and role in disease. Clin Chim Acta 2007;375:1-9. (Pubitemid 44584235)
8. Arola AM, Sanchez X, Murphy RT, Hasle E, Li H, Elliott PM et al. Mutations in PDLIM3 and MYOZ1 encoding myocyte Z line proteins are infrequently found in idiopathic dilated cardiomyopathy. Mol Genet Metab 2007;90:435-40. (Pubitemid 46484428)
9. Fatkin G. Molecular mechanisms of inherited cardiomyopathies. Mol Genet Metab 2007;90:435-40.
10. Mittmann C, Eschenhagen T, Scholz H. Cellular and molecular aspects of contractile dysfunction in heart failure. Cardiovasc Res 1998;39:267-75. (Pubitemid 28346522)
11. Mudd JO, Kass DA. Tackling heart failure in the twenty-first century. Nature 2008;451:919-28. (Pubitemid 351301747)
12. Seidman JG, Seidman C. The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell 2001;104:557-67. (Pubitemid 32201950)
13. Kamisago M, Sharma SD, DePalma SR, Solomon S, Sharma P, McDonough B et al. Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy. N Engl J Med 2000;343:1688-96.
14. Mirza M, Marston S, Willott R, Ashley C, Mogensen J, Mc Kenna W et al. Dilated cardiomyopathy mutations in three thin filament regulatory proteins result in a common functional phenotype. J Biol Chem 2005;5;280.
15. Olson TM, Michels VV, Thibodeau SN, Tai YS, Keating MT. Actin mutations in dilated cardiomyopathy, a heritable form of heart failure. Science 1998;280:750-2. (Pubitemid 28243352)
16. Gerull B, Gramlich M, Atherton J, McNabb M, Trombitás K, Sasse-Klaassen S et al. Mutations of TTN, encoding the giant muscle filament titin, cause familial dilated cardiomyopathy. Nat Genet 2002;30:201-4.
17. Tester DJ, Ackerman MJ. Cardiomyopathic channelopathic causes of sudden and unexplained death in infants and children. Annu Rev Med 2009;60:69-84.
18. Hershberger RE, Cowan J, Morales A, Siegfried JD. Progress with genetic cardiomyopathies: screening, counseling, and testing in dilated, hypertrophic, and arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circ Heart Fail 2009;2:253-61.
19. Franz WM, Müller M, Müller OJ, Herrmann R, Rothmann T, Cremer M et al. Association of nonsense mutation of dystrophin gene with disruption of sarcoglycan complex in X-linked dilated cardiomyopathy. Lancet 2000;355:1781-5. (Pubitemid 30265083)
20. Sanbe A, Osinska H, Saffitz JE, Glabe CG, Kayed R, Maloyan A et al. Desmin-related cardiomyopathy in transgenic mice: a cardiac amyloidosis. Proc Natl Acad Sci U S A 2004;101:10132-6. (Pubitemid 38891207)
21. Bauce B, Nava A, Beffagna G, Basso C, Lorenzon A, Smaniotto G et al. Multiple mutations in desmosomal proteins encoding genes in arrhythmogenic right ventricular cardiomyopathy/dysplasia. Heart Rhythm 2010;7:22-9.
22. Arad M, Seidman JG, Seidman CE. Phenotypic diversity in hypertrophic cardiomyopathy. Hum Mol Genet 2002;11:2499-506. (Pubitemid 35174714)
23. Kemp BE, Stapleton D, Campbell DJ, Chen ZP, Murthy S, Walter M et al. AMP-activated protein kinase, super metabolic regulator. Biochem Soc Trans 2003;31:162-8. (Pubitemid 36241420)
24. Arad M, Moskowitz IP, Patel W, Ahmad F, Perez-Atayde AR, Sawyer DB et al. Transgenic mice over-expressing mutant PRKAG2 define the cause of Wolff-Parkinson-White syndrome in glycogen storage cardiomyopathy. Circulation 2003;107:2850-6. (Pubitemid 36705997)
25. Blayney LM, Lai FA. Ryanodine receptor-mediated arrhythmias and sudden cardiac death. Pharmacol Ther 2009;123:151-77.
26. De la Fuente S, Van Langen IM, Postma AV, Bikker H, Meijer A. A case of catecholaminergic polymorphic ventricular tachycardia caused by two calsequestrin 2 mutations. Pacing Clin Electrophysiol 2008;31:916-9.
27. Zhang T, Guo T, Mishra S, Dalton ND, Kranias EG, Peterson KL et al. Phospholamban ablation rescues sarcoplasmic reticulum Ca(2+) handling but exacerbates cardiac dysfunction in CaMKIIdelta(C) transgenic mice. Circ Res 2010;106:354-62.
28. Said M, Becerra R, Palomeque J, Rinaldi G, Kaetzel MA, Diaz-Sylvester PL et al. Increased intracellular Ca2+ and SR Ca2+ load contribute to arrhythmias after acidosis in rat heart. Role of Ca2+/calmodulin-dependent protein kinase II. Am J Physiol Heart Circ Physiol 2008;295(4).
29. DeSantiago J, Maier LS, Bers DM. Phospholamban is required for CaMKII-dependent recovery of Ca transients and SR Ca reuptake during acidosis in cardiac myocytes. J Mol Cell Cardiol 2004;36:67-74. (Pubitemid 38084792)
30. Olson TM, Michels W, Ballew JD, Reyna SP, Karst ML, Herron KJ et al. Sodium Channel Mutation and Susceptibility to Heart Failure and Atrial Fibrillation. JAMA 2005;293:447-54.
31. Bienengraeber M, Olson TM, Selivanov VA, Kathmann EC, O'Cochlain F, Gao F et al. ABCC9 mutations identified in human dilated cardiomyopathy disrupt catalytic KATP channel gating. Nat Genet 2004;36:382-7. (Pubitemid 38437261)
32. Le Corvoisier P, Park HY, Rockman HA. Modifier genes and heart failure. Minerva Cardioangiol 2003;51:107-20. (Pubitemid 36827929)
33. McNamara DM, Holubkov R, Janosko K, Palmer A, Wang JJ, MacGowan GA et al. Pharmacogenetic interactions between beta-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. Circulation 2001;103:1644-8. (Pubitemid 32246611)
34. Herrmann S, Schmidt-Petersen K, Pfeifer J, Perrot A, Bit-Avragim N, Eichhorn C et al. A polymorphism in the endothelin-A receptor gene predicts survival in patients with idiopathic dilated cardiomyopathy. Eur Heart J 2001;22:1948-53. (Pubitemid 33054675)
35. Taku Y, Takeshi S, Tomohiko S, Tomosaburo T, Hideo T, Tetsuro T et al. Enhanced activity of ventricular Na+-HCO3- cotransport in pressure overload hypertrophy Am J Physiol Heart Circ Physiol 2007;293:H1254-H64.
36. Nozu K, Iijima K, Nozu Y, Ikegami E, Imai T, Fu XJ et al. A deep intronic mutation in the SLC12A3 gene leads to Gitelman sindrome. Pediatr Res 2009;66:590-3.
37. Konrad M, Vollmer M, Lemmink HH, van den Heuvel LP, Jeck N, Vargas-Poussou R et al. Mutations in the chloride channel gene CLCNKB as a cause of classic Bartter sindrome. J Am Soc Nephrol 2000;11:1449-59. (Pubitemid 30483461)
38. Liu JP. Studies of the molecular mechanisms in the regulation of telomerase activity. FASEB J 1999;13:2091-104.
39. Von Zglinicki T, Serra V, Lorenz M, Saretzki G, Lenzen-Grossimlighaus R, Gessner R et al. Short telomeres in patients with vascular dementia: an indicator of low antioxidative capacity and a possible risk factor? Lab Invest 2000;80:1739-47.
40. Brouilette SW, Moore JS, McMahon AD, Thompson JR, Ford I, Shepherd J et al. West of Scotland Coronary Prevention Study Group. Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. Lancet 2007;369:107-14. (Pubitemid 46073129)
41. Ogami M, Ikura Y, Ohsawa M, Matsuo T, Kayo S, Yoshimi N et al. Telomere shortening in human coronary artery diseases. Arterioscler Thromb Vasc Biol 2004;24:546-50. (Pubitemid 38326151)
42. Oexle K, Zwirner A. Advanced telomere shortening in respiratory chain disorders. Hum Mol Genet 1997;6:905-8. (Pubitemid 27239075)
43. Balasubramanyam M, Adaikalakoteswari A, Finny Monickaraj S, Mohan V. Telomere shortening and metabolic/vascular diseases. Indian J Med Res 2007;125:441-50.
44. Wizemann TM, Pardue ML. Exploring the biological contributions to human health: does sex matter? Washington, DC: National Academy Press; 2001.
45. Vaccarino V, Parsons L, Every NR, Barron HV, Krumholz HM. Sex-based differences in early mortality after myocardial infarction. National Registry of Myocardial Infarction 2 Participants. N Engl J Med 1999;341:217-25. (Pubitemid 29334519)
46. Bleumink GS, Knetsch AM, Sturkenboom MC, Straus SM, Hofman A, Deckers JW et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure. The Rotterdam Study. Eur Heart J 2004;25:1614-9. (Pubitemid 39209281)
47. Widder J, Pelzer T, von Poser-Klein C, Hu K, Jazbutyte V, Fritzemeier KH et al. Improvement of endothelial dysfunction by selective estrogen receptor-alpha stimulation in ovariectomized SHR. Hypertension 2003;42:991-6. (Pubitemid 37413743)
48. Deswal A, Bozkurt B. Comparison of morbidity in women versus men with heart failure and preserved ejection fraction. Am J Cardiol 2006;97:1228-31.
49. Grohe C, Briesemeister G, Stimpel M, Karas RH, Vetter H, Neyses L. Functional estrogen receptors in myocardial and myogenic cells. Circulation 1994;90:I-538.
50. Deroo BJ, Korach KS. Estrogen receptors and human disease. J Clin Invest 2006;116:561-70. (Pubitemid 43326860)
51. Mahmoodzadeh S, Eder S, Nordmeyer J, Ehler E, Huber O, Martus P et al. Estrogen receptor alpha upregulation and redistribution in human heart failure. FASEB J 2006;20:926-34. (Pubitemid 44943950)
52. Gabel SA, Walker VR, London RE, Steenbergen C, Korach KS, Murphy E. Estrogen receptor beta mediates gender differences in ischemia/ reperfusion injury. J Mol Cell Cardiol 2005;38:289-97. (Pubitemid 40215198)
53. Pelzer T, Loza PA, Hu K, Bayer B, Dienesch C, Calvillo L et al. Increased mortality and aggravation of heart failure in estrogen receptor-beta knockout mice after myocardial infarction. Circulation 2005;111:1492-8. (Pubitemid 40470643)
54. Schaible TF, Malhotra A, Ciambrone G, Scheuer J. The effects of gonadectomy on left ventricular function and cardiac contractile proteins in male and female rats. Circ Res 1984;54:38-49. (Pubitemid 14196446)
55. Sharkey LC, Holycross BJ, Park S, Shiry LJ, Hoepf TM, McCune SA et al. Effect of ovariectomy and estrogen replacement on cardiovascular disease in heart failure-prone SHHF/Mcc- fa cp rats. J Mol Cell Cardiol 1999;31:1527-37. (Pubitemid 29361119)
56. Arad M, Seidman CE, Seidman JG. AMP-activated protein kinase in the heart: role during health and disease. Circ Res 2007;100:474-88. (Pubitemid 46673257)
57. Xu Y, Arenas IA, Armstrong SJ, Plahta WC, Xu H, Davidge ST. Estrogen improves cardiac recovery after ischemia/reperfusion by decreasing tumor necrosis factor-alpha. Cardiovasc Res 2006;69:836-44. (Pubitemid 43227982)
58. Dash R, Kadambi V, Schmidt AG, Tepe NM, Biniakiewicz D, Gerst MJ et al. Interactions between phospholamban and beta-adrenergic drive may lead to cardiomyopathy and early mortality. Circulation 2001;103:889-96.
59. Kravtsov GM, Kam KW, Liu J, Wu S, Wong TM. Altered Ca(2-) handling by ryanodine receptor and Na(-)-Ca(2-) exchange in the heart from ovariectomized rats: role of protein kinase A. Am J Physiol Cell Physiol 2007;292:C1625-C35.
60. Chu SH, Sutherland K, Beck J, Kowalski J, Goldspink P, Schwertz D. Sex differences in expression of calcium-handling proteins and beta-adrenergic receptors in rat heart ventricle. Life Sci 2005;76:2735-49. (Pubitemid 40404060)
61. Nohammer C, Brunner F, Wolkart G, Staber PB, Steyrer E, Gonzalez FJ et al. Myocardial dysfunction and male mortality in peroxisome proliferator- activated receptor alpha knockout mice overexpressing lipoprotein lipase in muscle. Lab Invest 2003;83:259-69. (Pubitemid 36255370)
62. Jeong S, Yoon M. Inhibition of the actions of peroxisome proliferatoractivated receptor alpha on obesity by estrogen. Obesity (Silver Spring) 2007;15:1430-40. (Pubitemid 47110906)
63. Jenkins DJ, Kendall CW, Marchie A, Faulkner DA, Wong JM, de Souza R et al. Effects of a dietary portfolio of cholesterol- lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA 2003;290:502-10. (Pubitemid 37430504)
64. Sacks FM, Lichtenstein A, Van Horn L, Harris W, Kris-Etherton P, Winston M. Soy protein, isoflavones, and cardiovascular health: an American Heart Association Science Advisory for professionals from the Nutrition Committee. Circulation 2006;113:1034-44. (Pubitemid 43879479)
65. Paris F, Jeandel C, Servant N, Sultan C. Increased serum estrogenic bioactivity in three male newborns with ambiguous genitalia: a potential consequence of prenatal exposure to environmental endocrine disruptors. Environ Res 2006;100:39-43. (Pubitemid 41767723)
66. Assinder S, Davis R, Fenwick M, Glover A. Adult-only exposure of male rats to a diet of high phytoestrogen content increases apoptosis of meiotic and post-meiotic germ cells. Reproduction 2007;133.11-9.
67. Mueller SO, Simon S, Chae K, Metzler M, Korach KS. Phytoestrogens and their human metabolites show distinct agonistic and antagonistic properties on estrogen receptor alpha (ERalpha) and ERbeta in human cells. Toxicol Sci 2004;80:14-25. (Pubitemid 38967392)
68. Vera R, Sanchez M, Galisteo M, Villar IC, Jimenez R, Zarzuelo A et al. Chronic administration of genistein improves endothelial dysfunction in spontaneously hypertensive rats: involvement of eNOS, caveolin and calmodulin expression and NADPH oxidase activity. Clin Sci (Lond) 2007;112:183-91.
69. Cooke PS, Selvaraj V, Yellayi S. Genistein, estrogen receptors, and the acquired immune response. J Nutr 2006;136:704-8. (Pubitemid 43363758)
70. Kumi-Diaka J, Sanderson NA, Hall A. The mediating role of caspase-3 protease in the intracellular mechanism of genistein-induced apoptosis in human prostatic carcinoma cell lines, DU145 and LNCaP. Biol Cell 2000;92:595-604. (Pubitemid 32366627)
71. Yoon HS, Moon SC, Kim ND, Park BS, Jeong MH, Yoo YH. Genistein induces apoptosis of RPE-J cells by opening mitochondrial PTP. Biochem Biophys Res Commun 2000;276:151-6.
72. Stauffer BL, Konhilas JP, Luczak ED, Leinwand LA. Soy diet worsens heart disease in mice. J Clin Invest 2006;116:209-16. (Pubitemid 43121806)
73. Reinli K, Block G. Phytoestrogen content of foods: a compendium of literature values. Nutr Cancer 1996;26:123-48. (Pubitemid 26300193)
74. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994;308:367-72. (Pubitemid 24078498)
75. Dale KM, Coleman CI, Shah SA, Patel AA, Kluger J, White CM. Impact of gender on statin efficacy. Curr Med Res Opin 2007;23:565-74. (Pubitemid 46456904)
76. Knopp RH, Retzlaff BM. Saturated fat prevents coronary artery disease? An American paradox. Am J Clin Nutr 2004;80:1102-3. (Pubitemid 41350668)
77. Cooke PS, Naaz A. Role of estrogens in adipocyte development and function. Exp Biol Med (Maywood) 2004;229:1127-35. (Pubitemid 39602255)
78. Tchernof A, Desmeules A, Richard C, Laberge P, Daris M, Mailloux J et al. Ovarian hormone status and abdominal visceral adipose tissue metabolism. J Clin Endocrinol Metab 2004;89:3425-30. (Pubitemid 38951915)
79. D'Eon TM, Souza SC, Aronovitz M, Obin MS, Fried SK, Greenberg AS. Estrogen regulation of adiposity and fuel partitioning: evidence of genomic and non-genomic regulation of lipogenic and oxidative pathways. J Biol Chem 2005;280:35983-91. (Pubitemid 41633867)
80. Wade GN, Gray JM, Bartness TJ. Gonadal influences on adiposity. Int J Obes 1985;9(Suppl 1):83-92. (Pubitemid 16173371)
81. Penza M, Montani C, Romani A, Vignolini P, Pampaloni B, Tanini A et al. Genistein affects adipose tissue deposition in a dose-dependent and genderspecific manner. Endocrinology 2006;147:5740-51. (Pubitemid 44833490)
82. Klinge CM, Risinger KE, Watts MB, Beck V, Eder R, Jungbauer A. Estrogenic activity in white and red wine extracts. J Agric Food Chem 2003;51:1850-7.
83. Bradamante S, Barenghi L, Villa A. Cardiovascular protective effects of resveratrol. Cardiovasc Drug Rev 2004;22:169-88. (Pubitemid 39391187)
84. Liew R, Stagg MA, MacLeod KT, Collins P. The red wine polyphenol, resveratrol, exerts acute direct actions on guinea-pig ventricular myocytes. Eur J Pharmacol 2005;519:1-8. (Pubitemid 43181157)
85. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003;425:191-6. (Pubitemid 37150899)
86. Arany Z, He H, Lin J, Hoyer K, Handschin C, Toka O et al. Transcriptional coactivator PGC-1 alpha controls the energy state and contractile function of cardiac muscle. Cell Metab 2005,1:259-71. (Pubitemid 43960608)
87. Baron S, Escande A, Alberola G, Bystricky K, Balaguer P, Richard-Foy H. Estrogen receptor alpha and the activating protein-1 complex cooperate during insulin-like growth factor-I-induced transcriptional activation of the pS2/TFF1 gene. J Biol Chem 2007;282:11732-41. (Pubitemid 47100665)
88. Mercier I, Mader S, Calderone A. Tamoxifen and ICI 182,780. Negatively influenced cardiac cell growth via an estrogen receptor independent mechanism. Cardiovasc Res 2003;59:883-92. (Pubitemid 38366244)
89. Backs J, Olson EN. Control of cardiac growth by histone acetylation/deacetylation. Circ Res 2006;98:15-20.
90. Thiagalingam S, Cheng KH, Lee HJ, Mineva N, Thiagalingam A, Ponte JF. Histone deacetylases: unique players in shaping the epigenetic histone code. Ann NY Acad Sci 2003;983:84-100. (Pubitemid 36399322)
91. XuWS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007;26:5541-52.
92. Zhang CL, McKinsey TA, Chang S, Antos CL, Hill JA, Olson EN. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 2002;110:479-88. (Pubitemid 35232291)
93. Michan S, Sinclair D. Sirtuins in mammals: insights into their biological function. Biochem J 2007;404:1-13. (Pubitemid 46788079)
94. Alcendor RR, Gao S, Zhai P, Zablocki D, Holle E, Yu X et al. Sirt 1 regulates aging and resistance to oxidative stress in the heart. Circ Res 2007;100:1512-21. (Pubitemid 46834764)
95. Pillai JB, Gupta M, Rajamohan SB, Lang R, Raman J, Gupta MP. Poly(ADPribose) polymerase-1-deficient mice are protected from angiotensin II-induced cardiac hypertrophy. Am J Physiol Heart Circ Physiol 2006;291:H1545-53. (Pubitemid 44497657)
96. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-97.
97. ThumT, Galuppo P,Wolf C, Fiedler J, Kneitz S, van Laake et al. MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation 2007;116:258-67. (Pubitemid 47196561)
98. Ikeda S, Kong SW, Lu J, Bisping E, Zhang H, Allen PD et al. Altered microRNA expression in human heart disease. Physiol Genomics 2007;31:367-73. (Pubitemid 350127777)
99. Wienholds E, Kloosterman WP, Miska E, Alvarez-Saavedra E, Berezikov E, de Bruijn E et al. MicroRNA expression in zebrafish embryonic development. Science 2005;309:310-1. (Pubitemid 40967869)
100. Sayed D, Hong C, Chen IY, Lypowy J, Abdellatif M MicroRNAs play an essential role in the development of cardiac hypertrophy. Circ Res 2007;100:416-24.
101. Cheng Y, Ji R, Yue J, Yang J, Liu X, Chen H et al. MicroRNAs are aberrantly expressed in hypertrophic heart. Do they play a role in cardiac hypertrophy? Am J Pathol 2007;170:1831-40. (Pubitemid 47339258)
102. Thum T, Galuppo P, Wolf C, Fiedler J, Kneitz S, van Laake LW et al. MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation 2007;116:258-67. (Pubitemid 47196561)